Cargando…

Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model

PURPOSE: Breast cancer risks for CHEK2 and ATM pathogenic variant (PV) carriers are modified by an 86-single nucleotide polymorphism polygenic risk score (PRS) and individual clinical factors. Here, we describe comprehensive risk prediction models for women of European ancestry combining PV status,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gallagher, Shannon, Hughes, Elisha, Kurian, Allison W., Domchek, Susan M., Garber, Judy, Probst, Braden, Morris, Brian, Tshiaba, Placede, Meek, Stephanie, Rosenthal, Eric, Roa, Benjamin, Slavin, Thomas P., Wagner, Susanne, Weitzel, Jeffrey, Gutin, Alexander, Lanchbury, Jerry S., Robson, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2021
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238281/ https://www.ncbi.nlm.nih.gov/pubmed/34322652 http://dx.doi.org/10.1200/PO.20.00484

Ejemplares similares

Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk
por: Hughes, Elisha, et al.
Publicado: (2020)

Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes
por: Gallagher, Shannon, et al.
Publicado: (2020)

Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing
por: Hughes, Elisha, et al.
Publicado: (2021)

A Case-Control Study to Add Volumetric or Clinical Mammographic Density into the Tyrer-Cuzick Breast Cancer Risk Model
por: Brentnall, Adam R, et al.
Publicado: (2019)

Comparative Analysis between the Gail, Tyrer-Cuzick and BRCAPRO Models for Breast Cancer Screening in Brazilian Population
por: Stevanato, Kely Paviani, et al.
Publicado: (2019)

Breast cancer risk prediction using Tyrer-Cuzick algorithm with an 18-SNPs polygenic risk score in a European population with below-average breast cancer incidence
por: Oblak, Tjaša, et al.
Publicado: (2023)

Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort
por: Brentnall, Adam R., et al.
Publicado: (2015)

Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry
por: Pal Choudhury, Parichoy, et al.
Publicado: (2021)

Performance of the Gail and Tyrer-Cuzick breast cancer risk assessment models in women screened in a primary care setting with the FHS-7 questionnaire
por: Vianna, Fernanda Sales Luiz, et al.
Publicado: (2019)

Use of Receiver Operating Characteristic (ROC) Curve Analysis for Tyrer-Cuzick and Gail in Breast Cancer Screening in Jiangxi Province, China
por: Zhang, Le, et al.
Publicado: (2018)

Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry Composition
por: Hughes, Elisha, et al.
Publicado: (2022)

Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I
por: Warwick, Jane, et al.
Publicado: (2014)

Integration of a Cross-Ancestry Polygenic Model With Clinical Risk Factors Improves Breast Cancer Risk Stratification
por: Tshiaba, Placede T., et al.
Publicado: (2023)

Association of genetic variants in ATR-CHEK1 and ATM-CHEK2 pathway genes with risk of colorectal cancer in a Chinese population
por: Wang, Shijia, et al.
Publicado: (2018)

PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS
por: Southey, Melissa C, et al.
Publicado: (2016)

Incorporating Truncating Variants in PALB2, CHEK2 and ATM into the BOADICEA Breast Cancer Risk Model
por: Lee, Andrew J., et al.
Publicado: (2016)

Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers
por: Toss, Angela, et al.
Publicado: (2021)

Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks
por: Decker, Brennan, et al.
Publicado: (2017)

Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
por: Constantinidou, Anastasia, et al.
Publicado: (2022)

High risk of breast cancer in women with biallelic pathogenic variants in CHEK2
por: Rainville, Irene, et al.
Publicado: (2020)

Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D
por: Graffeo, R., et al.
Publicado: (2022)

The association between age at breast cancer diagnosis and prevalence of pathogenic variants
por: Daly, Mary B., et al.
Publicado: (2023)

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
por: Patel, Jai N., et al.
Publicado: (2018)

Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk
por: Baynes, Caroline, et al.
Publicado: (2007)

The CHEK 2 GENE mutations and the risk of Gastric cancer
por: Teodorczyk, Urszula, et al.
Publicado: (2012)

Selenium and cancer risk in CHEK2 mutation carriers
por: Gupta, Satish, et al.
Publicado: (2012)

Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care—Checking CHEK2
por: Bychkovsky, Brittany L., et al.
Publicado: (2022)

Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories?
por: Byrnes, Graham B, et al.
Publicado: (2008)

The risk of breast cancer in women with a CHEK2 mutation
por: Cybulski, Cezary, et al.
Publicado: (2012)

CHEK2 mutations as markers for high risk of breast cancer
por: Cybulski, Cezary, et al.
Publicado: (2012)

ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk
por: Stolarova, Lenka, et al.
Publicado: (2023)

CHEK2 (∗)1100delC Mutation and Risk of Prostate Cancer
por: Hale, Victoria, et al.
Publicado: (2014)

Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic ATM Alterations
por: Hannan, Zain, et al.
Publicado: (2021)

Linkage Disequilibrium Mapping of CHEK2: Common Variation and Breast Cancer Risk
por: Einarsdóttir, Kristjana, et al.
Publicado: (2006)

The Prevalence of CHEK1 and CHEK2 Mutations in Prostate Cancer: a Retrospective Cohort Study
por: Alorjani, Mohammed, et al.
Publicado: (2023)

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
por: Knappskog, Stian, et al.
Publicado: (2012)

Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma
por: Havranek, Ondrej, et al.
Publicado: (2015)

Rare variants in BRCA2 and CHEK2 are associated with the risk of urinary tract cancers
por: Ge, Yuqiu, et al.
Publicado: (2016)

Genetic modifiers of CHEK2*1100delC associated breast cancer risk
por: Muranen, Taru A., et al.
Publicado: (2016)

Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer
por: Wang, Yufei, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_307c647pgjotkljbvv5n5sfuqn